Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-04-24 Annual Report
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2023. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and mentions an audit report with an unqualified opinion by an accounting firm. The document is over 6,800 characters, indicating it is substantive and not just an announcement. The content covers company business overview, financial performance, shareholder structure, and other key annual report elements. Therefore, this document is the actual Annual Report (10-K equivalent). FY 2023
2024-04-24 Chinese
2023年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report' and includes detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. It covers the fiscal year 2023 for Beijing Northland Biotechnology Co., Ltd. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. FY 2023
2024-04-24 Chinese
2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, evaluations of the external auditor, and overall performance during the year 2023. The content focuses on the audit committee's supervision and evaluation of audit work rather than presenting full financial statements or a complete audit report. The document length is 1626 characters, which is relatively short and more of a committee report rather than a full audit report or annual report. It is not an announcement of a report publication but a substantive report on the audit committee's duties and activities. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports. FY 2023
2024-04-24 Chinese
中泰证券关于诺思兰德第一期股权激励计划第三个行权期、预留部分股票期权第二个行权期行权条件及限制性股票第三个解除限售期解除限售条件未成就暨注销部分股票期权及回购注销部分限制性股票事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a company's first equity incentive plan, specifically discussing the conditions for stock option exercise periods, restricted stock release periods, and the cancellation and repurchase of certain stock options and restricted stocks. It contains detailed financial and approval information about stock option cancellations and repurchases, including quantities, prices, and board approvals. The document is not a general annual or quarterly report, nor is it a simple announcement or voting result. It is a detailed advisory report on equity incentive plan matters, which aligns with the category of Capital/Financing Update (CAP) because it deals with stock option exercises, cancellations, and repurchases affecting the company's capital structure and equity incentives. The document length is substantial (over 11,000 characters), and it contains substantive financial and procedural details, not just an announcement or certification. Therefore, the best fitting classification is CAP with high confidence.
2024-04-24 Chinese
2023年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制有效性自我评价报告' which translates to '2023 Annual Internal Control Effectiveness Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2023. The content includes governance structure, risk assessment, control activities, information and communication, and control supervision, as well as internal control defect recognition and rectification. It is a comprehensive internal control report rather than a general annual report or financial statement. The document is about internal control effectiveness and self-evaluation, which aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and compliance with regulatory internal control standards. The document length (7316 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-24 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司2023年度募集资金存放与使用情况的核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "核查报告" (Verification Report) regarding the 2023 annual fundraising funds deposit and usage situation of Beijing Nuosiland Biotechnology Co., Ltd. It is issued by Zhongtai Securities as the sponsor institution. The content details the deposit, usage, management, and supervision of the fundraising funds for the year 2023, including tables of fund usage, bank accounts, and cash management products. It also includes an auditor's opinion from Zhongshen Asia Pacific CPA firm on the fundraising funds usage for 2023. The document is about the verification and audit of the company's fundraising funds usage for a specific year, which aligns with the definition of an Audit Report / Information (AR) as it is a standalone audit report on the use of raised funds, not a full annual report or interim report. The document length is substantial (15,000 characters), and it contains detailed financial and compliance information about fundraising funds usage, not just an announcement or summary. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2023
2024-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.